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selected. Two independent reviewers read the survival probabilities from KM
curves using an open source digitising software (Engauge digitizer). HRs for non-
overlapping time intervals were calculated from the estimated survival probabili-
ties and combined in a stratified way across time intervals to obtain an overall HR
using the spreadsheet by Tierney and colleagues. The estimated HR was compared
with the reported HR for each study. RESULTS: A mean error on the log scale of
0.001 (95%CI: 0.022, 0.019) was observed. This implies that by taking the expo-
nentials, if the reported HR is 0.750, then the estimated HR would be 0.749. The
95%CI for the mean error spans zero indicating any systematic error is likely to be
small and should not influence results in most analytic situations. Mean absolute
error on the log scale was 0.027 (95%CI: 0.016, 0.037) indicating calculated HR lie
within a factor of exponential (0.027) either side of the original value. No change in
the direction of the treatment effect was observed in the estimated HR (95%CI) for
any of the selected study. Reconstructed KM curves presented high accuracy and
reproducibility. CONCLUSIONS: KM curves could be potential source of data and it
is recommended that these should be used more frequently to estimate HR (95%
CI), where not reported explicitly, for conducting meta-analysis in systematic re-
views.
PRM2
ASSESSING RELATIVE CLINICAL VALUE WITHIN THREE METASTATIC DISEASES
Karweit J1, Wolfe S1, Kotapati S2, Lees M3, Abernethy AP4
1IMS Consulting Group, New York, NY, USA, 2Bristol-Myers Squibb Pharmaceuticals,
Wallingford, CT, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Duke Clinical Research
Institute and Duke Cancer Institute, Durham, NC, USA
OBJECTIVES: As more innovative oncology agents become available, budget limi-
tations are necessitating deeper value assessments of products. Previous research
demonstrated that examining a variety of key survival metrics is required to fully
define the value of an anti-neoplastic intervention. Here we examine how various
survival metrics compare across 3 major metastatic tumor types, chosen because
of the introduction of new therapeutics in the past year: melanoma, prostate and
lung cancer. METHODS: We conducted a literature-based review of pivotal clinical
trial data supporting new therapeutics in these tumor types from 2006-2012 and
selected all products with demonstrated overall survival benefit in the metastatic
setting: vemurafinib, ipilimumab for melanoma; cabazitaxel, abiraterone, sipuleu-
cel-T for prostate cancer; pemetrexed, erlotinib, and bevacizumab for lung cancer.
Crizotinib was excluded having not reached median overall survival (OS) at ap-
proval. We compared products on four survival metrics: median OS, mean OS,
1-year survival, and number needed to treat to avoid one event (NNT). RESULTS:
Despite variations in patient tumor types , the products showed a narrow range of
median OS improvement. However, greater variability was seen across other met-
rics: in lung cancer, pemetrexed presented the greater mean OS improvement,
while erlotinib demonstrated greater 1-year survival and lower NNT. In melanoma,
vemurafenib and ipilimumab demonstrated the same number of months of me-
dian OS improvement in their respective clinical trials; however, ipilimumab dem-
onstrated greater mean OS, 1-year survival, and lower NNT. In prostate cancer,
sipuleucel-T demonstrated better mean OS improvement, whereas abiraterone
had better 1-year survival and lower NNT. CONCLUSIONS: Drugs are being evalu-
ated with remarkably similar median OS benefits for metastatic patient popula-
tions. Side-by-side comparisons that take multiple endpoints into account can
assist decison makers to better understand total clinical benefit in context and
contribute to thoughtful resource management, especially when median OS ben-
efit may be so similar.
PRM3
TURNING THE TABLES TO ADDRESS THE REAL VALUE OF REAL-WORLD
OBSERVATIONAL STUDIES OF NOVEL ANTI-CANCER AGENTS IN MULTIPLE
MYELOMA
Gaultney JG1, Franken MG1, Redekop WK1, Huijgens PC2, Uyl-de Groot CA1, Sonneveld P3
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands,
2VU University Medical Center, Amsterdam, The Netherlands, 3Erasmus Medical Center,
Rotterdam, The Netherlands
OBJECTIVES: Due to pressure to provide rapid access despite uncertainty of a
drug’s real-world value, decision makers often require evidence from outcomes
research. We assessed whether a retrospective observational design can confirm
the trial-based efficacy for the novel agent bortezomib in advanced multiple my-
eloma and identify reasons for any discrepancies. METHODS: Two patient popu-
lations were included: real-world patients in the Netherlands (n72) and the bort-
ezomib pivotal trial population (n333). Data on real-world patients were
retrospectively collected from hospital records (period: 2001-2009). Baseline prog-
nostic factors, treatment patterns, safety and clinical outcomes were compared.
RESULTS: Overall response rates (49% versus 38%; p0.1) and time to progression
(median: 6.8 versus 6.2 months; p0.6) was similar compared to the trial though
the frequency of patient follow-up and definitions used for clinical outcomes var-
ied in daily practice. Overall survival was lower compared to the trial (median: 17.2
versus 29.8 months; p0.01) on account of differences in patient prognosis and use
of the drug. Daily practice patients were more heavily pre-treated in a shorter time
frame at baseline. Practice variation was observed in daily practice with the ma-
jority receiving bortezomib in combination with one or more drugs (68%). Conser-
vative administration was observed with lower cumulative dosages and fewer
treatment cycles (4 versus 6) in daily practice. Safety-related outcomes could not be
compared since this information in patient charts was frequently not detailed.
CONCLUSIONS: A retrospective design confirmed some but not all efficacy end-
points and identified reasons for discrepancies. Evidence generated from retro-
spective studies is complementary to that generated in a trial. Despite threats to
validity of the treatment effect, a retrospective design will generate valuable evi-
dence about who receives the drug and how it is given, which facilitates a feedback
loop to decision makers about ways to improve patient care and ultimately the
drug’s real-world value.
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OBJECTIVES: Immunosuppressive drugs have been subject to different evidence-
based assessments including evaluations along the regulatory process of the EMA
or reimbursement decisions by European HTA agencies. The objective of this re-
search was to review and compare the criteria applied for assessing immunosup-
pressive drugs in renal transplantation. Particular focus was set on the consisten-
cies and differences regarding assessment between the German IQWiG compared
to other European agencies. METHODS: A review of reports and guidelines on
subjects relevant for evidence-based assessment of immunosuppressive therapies
for renal transplantation which were published by EMA, IQWiG, and the European
HTA agencies of France, Scotland, Sweden and UK. The search was restricted to
documents in English or German. RESULTS: We identified relevant documents
from five agencies: one guidance document from EMA, HTA reports from the NICE
in UK, one advice from the SMC in Scotland, assessment summaries from the
French HAS and one report of early benefit assessment from the German IQWiG. No
relevant document was identified from the Swedish SBU. The EMA document pro-
vides guidance for planning of pivotal studies to evaluate safety and efficacy. The
HAS, NICE and SMC appraisals give advice for using immunosuppressive therapies
for renal transplantation and the IQWiG report assessed the additional benefit of
one new immunosuppressant. All documents recommended randomized con-
trolled trials (RCT) or systematic reviews of RCTs as the highest level of evidence.
Differences were in the clinical endpoints considered. In contrast to other agencies
the IQWiG did exclude the endpoints ‘graft function’ and ‘biopsy-confirmed acute
rejection’ from evaluation and did not consider compliance as relevant.
CONCLUSIONS: All agencies consistently recommend a similar standard for the
level of evidence. However, as long as there is no harmonization on the relevant
endpoints considered for evidence-based assessments, the different requirements
of local agencies should be considered when designing clinical trials and planning
statistical analyses.
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OBJECTIVES: According to the social law in Germany the Statutory Health Insur-
ance (GKV) has to address the three dimensions of disease: mortality, morbidity,
and quality of life. Consequently, the recently introduced EBA in Germany is group-
ing the benefits and the related endpoints into these dimensions. Our aim was to
examine the relative importance of each of those dimensions with regards to the
suggested benefit claims by the Institute for Quality and Efficiency in Health Care
(IQWiG). METHODS: The review includes EBAs that were started in 2011. The Joint
Federal Committee’s (GBA) webpage (http://www.g-ba.de/informationen/nutzen-
bewertung/) was used to obtain the respective IQWiG benefit assessments. The
benefit that IQWiG suggested was analysed for each assessment and the attribu-
tion of benefit to each of the three disease domains was examined. RESULTS:
Twenty-four EBAs were started in 2011. Two Orphan indications were excluded
from the analysis (Tafamidis Meglumin, Pirfenidon). In ten EBAs IQWiG suggested
a benefit for the related medication at least in one disease dimension and/or one
subgroup (Telaprevir, Abirateronacetat, Boceprevir, Ipilimumab, Belatacept,
Apixaban, Cabazitaxel, Fingolimod, Ticacrelor, Eribulin). In Abirateronacetat, Ipili-
mumab, Cabazitaxel, Ticacrelor, and Eribulin IQWiG suggested a mortality benefit.
With Ticacrelor IQWiG discriminated overall and cardiovascular mortality. In Tel-
aprevir, Abirateronacetat, Boceprevir, Apixaban, and Ticacrelor IQWiG suggested a
morbidity benefit. Due to the small number of eligible patients Fingolimod was
ultimately not examined regarding morbidity. No benefits were reported in the
dimension of Quality of Life. Side effects that were considered to cause additional
harm to patients and that negatively impacted the overall benefit rating were re-
ported in five EBAs: Boceprevir, Ipilimumab, Apixaban, Cabazitaxel, Eribulin.
CONCLUSIONS: In all reviewed assessments no benefit was attributed to Quality of
Life. The disease dimensions morbidity and mortality were of equal importance.
However, definitions of benefit within the dimension morbidity were very hetero-
geneous across the various EBAs
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OBJECTIVES: UK Pharma considers the UK a leading environment for the conduct
of Real World (RW) health care studies due to the influence of NICE, the cradle-to-
grave health care provided by the NHS, with GPs as the co-ordinators of care for
every patient and the widespread use of e-health records. Is there evidence for this
from research output? We reviewed abstracts published last year at ISPOR as one
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